Hanall Biopharma, Stock Price +1.97% at This Hour... 3,334,029 Shares Net Bought by Individuals in the Last 5 Days

Hanall Biopharma is trading at 25,850 KRW as of 12:30 PM on the 5th, up 1.97% from the previous day. The trading volume is 1,515,741 shares, which is 49.32% of the previous day's volume. Hanall Biopharma is known as an R&D-focused pharmaceutical and bio company.

On February 4th, Jiha Kim, a researcher at Meritz Securities, stated, "The stock price plunged 24% due to the suspension of the TED clinical trial, and there will be little fluctuation in the stock price until the trial resumes. The Chinese partner Harbor Biomed's ITP and MG clinical trial participants had no safety issues. The rise in LDL levels is likely a TED-specific issue, so the expectation for Anti-FcRn remains valid. Since the resumption decision for the clinical trial is expected in February, the MG and WAIHA trials are also uncertain, so a pause is necessary." He set the target price for Hanall Biopharma at 45,000 KRW.

Over the past five days, individual investors have net purchased 3,334,029 shares of Hanall Biopharma, while foreigners and institutions have net sold 478,439 shares and 2,851,616 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.